GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Argenica Therapeutics Ltd (ASX:AGN) » Definitions » Quick Ratio

Argenica Therapeutics (ASX:AGN) Quick Ratio : 4.25 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Argenica Therapeutics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Argenica Therapeutics's quick ratio for the quarter that ended in Dec. 2023 was 4.25.

Argenica Therapeutics has a quick ratio of 4.25. It generally indicates good short-term financial strength.

The historical rank and industry rank for Argenica Therapeutics's Quick Ratio or its related term are showing as below:

ASX:AGN' s Quick Ratio Range Over the Past 10 Years
Min: 4.25   Med: 12.29   Max: 129.59
Current: 4.25

During the past 3 years, Argenica Therapeutics's highest Quick Ratio was 129.59. The lowest was 4.25. And the median was 12.29.

ASX:AGN's Quick Ratio is ranked better than
55.17% of 1546 companies
in the Biotechnology industry
Industry Median: 3.595 vs ASX:AGN: 4.25

Argenica Therapeutics Quick Ratio Historical Data

The historical data trend for Argenica Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argenica Therapeutics Quick Ratio Chart

Argenica Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
Quick Ratio
17.07 12.29 5.09

Argenica Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Quick Ratio Get a 7-Day Free Trial 92.97 12.29 6.24 5.09 4.25

Competitive Comparison of Argenica Therapeutics's Quick Ratio

For the Biotechnology subindustry, Argenica Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Argenica Therapeutics's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Argenica Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Argenica Therapeutics's Quick Ratio falls into.



Argenica Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Argenica Therapeutics's Quick Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Quick Ratio (A: Jun. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(9.54-0)/1.874
=5.09

Argenica Therapeutics's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(8.62-0)/2.026
=4.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Argenica Therapeutics  (ASX:AGN) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Argenica Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Argenica Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Argenica Therapeutics (ASX:AGN) Business Description

Traded in Other Exchanges
N/A
Address
117 Broadway, Unit 4, Nedlands, WA, AUS, 6009
Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.

Argenica Therapeutics (ASX:AGN) Headlines

No Headlines